Impact of pain and nonpain co-morbidities on opioid use in women with endometriosis

Georgine Lamvu, Ahmed M. Soliman, Beverly Johns, Jamie B. Vora, Stephanie J. Estes

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Aim: To evaluate impact of co-morbidities on opioid use in endometriosis. Patients & m ethods: This was a retrospective analysis of data obtained from the Symphony Health database (July 2015-June 2018), which contains medical and pharmacy claims information on 79,947 women with endometriosis. Relative risk (RR) of postdiagnosis opioid use and supply duration associated with baseline co-morbidities were determined. Results: Women with endometriosis using opioids at baseline were 61% more likely to receive opioids postdiagnosis (RR: 1.61; 95% CI: 1.59-1.63). Risk of prolonged opioid supply postdiagnosis was highest for those with prolonged supply at baseline (RR: 21.14; 20.14-22.19), and was 1.32 (1.26-1.38) for patients with ≥1 co-morbidity, 1.37 (1.31-1.43) for pain co-morbidities and 1.07 (1.04-1.11) for psychiatric co-morbidities. Conclusion: Risk of opioid use after endometriosis diagnosis was greater in patients who used opioids before diagnosis. Risk of prolonged opioid use was greater if co-morbidities existed before diagnosis.

Original languageEnglish (US)
Pages (from-to)17-27
Number of pages11
JournalJournal of Comparative Effectiveness Research
Issue number1
StatePublished - Jan 2021

All Science Journal Classification (ASJC) codes

  • Health Policy


Dive into the research topics of 'Impact of pain and nonpain co-morbidities on opioid use in women with endometriosis'. Together they form a unique fingerprint.

Cite this